Davis Capital Management
PTCT icon

Davis Capital Management’s PTC Therapeutics PTCT Stock Holding History

Davis Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$194 Sell
3
-2
-40% -$146 ﹤0.01% 860
2026
Q2 		$408 Buy
+5
New +$361 ﹤0.01% 652

Other funds holding PTCT

Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
Oak Ridge Investments
Oak Ridge Investments Chicago, Illinois $1.68B AUM 48.52% 1-Year Est. Return
Empirical Wealth Management
Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Yousif Capital Management
Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Davis Capital Management's PTCT Position: Q3 2026 in Review

Davis Capital Management reduced its PTC Therapeutics (PTCT) stake by 40% in Q3 2026, selling an estimated $146 and leaving 3 shares worth $194. The position accounts for ﹤0.01% of the portfolio, ranked #860.

Davis Capital Management first reported a position in PTCT in Q2 2026 and has held it in 2 quarters since. The position peaked at $408 in Q2 2026. 85 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • Davis Capital Management held 3 shares of PTC Therapeutics worth $194 as of Q3 2026.
  • Davis Capital Management sold 2 PTC Therapeutics shares in Q3 2026, an estimated $146.
  • PTC Therapeutics made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #860 holding.
  • Davis Capital Management first reported a position in PTC Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Davis Capital Management's PTC Therapeutics position peaked at $408 in Q2 2026.
  • 85 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.